Reference: 4000.1 Effective: 2023 Review: 2025 Page: 1 of 1

FORMULARY

<u>Labetalol</u>

Class of Drug	Antihypertensive with selective alpha-1 and non-selective beta-antagonist effects.
Mechanism of Action	Combines both selective, competitive, alpha- adrenergic blocking and non-selective, competitive, beta-adrenergic blocking activity in a single substance. The ratio of alpha-to beta- blocking has been estimated at 1:7 following intravenous administration. Due to the alpha 1 receptor blocking activity of labetalol, blood pressure is lowered more in the standing patient than in the supine position, and symptoms of postural hypotension can occur.
Indications	Severe hypertension.
Contraindications	Bronchial asthma. Cardiogenic shock. Greater than first degree heart block. Severe bradycardia. Other conditions associated with severe and prolonged hypotension. Patients with known hypersensitivity.
Adverse Effects	Fatigue, headache, paresthesia, syncope, orthostatic hypotension, ventricular dysrhythmias, nasal stuffiness, GI distress, sexual dysfunction, urinary retention, muscle spasm, bronchospasm, rash.
Precautions	Use with caution in patients with impaired hepatic or renal function since metabolism of the drug may be diminished.
Dosing/Administration	Adult: First dose of 20 mg slow IVP. May repeat every 10 min with additional doses of 40 mg and then 80 mg repeated at 80 mg until a maximum of 300 mg is administered. Obstetrical: 20 mg slow IVP (over 2 min). May repeat every 10 min with additional doses of 40 mg and then 80 mg until a maximum of 300 mg is administered. Continuous Infusion: Mix 200 mg in 250 mL of D5W and administer at 1 – 2 mg/min up to 60 mg/hour.
Pregnancy Category	C-Uncertain safety – animal studies show adverse effect but no human studies exist